Blue Earth Therapeutics

Blue Earth Therapeutics is a clinical-stage biotechnology company developing targeted radiopharmaceutical therapies for cancer.

Its pipeline centres on prostate-specific membrane antigen-targeted radioligand therapies using both beta- and alpha-emitting radionuclides, designed to deliver high radiation doses to tumour cells while minimising exposure to healthy tissue.

Lead programmes for metastatic castrate-resistant prostate cancer are in Phase 2 clinical trials, with dosing initiated at UK NHS sites in 2026.